A Randomized Phase III Trial of Platinum-based Chemotherapy plus chemotherapy and antibody drugs with experimental immunotherapy versus standard-of-care Platinum-based Chemotherapy plus chemotherapy and anti-body drugs in Metastatic (stage IVB), Persistent, or Recurrent Cervical Cancer

UVA Tracking #
HSR200129
Principal Investigator
Linda R Duska
Contact
Sheena Clift
Contact Phone
434.924.2745
Official Trial Title
A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Study Description

The UVA Cancer Center seeks women ages 18 and over who have metastatic, persistent or recurrent cervical
cancer (where surgery and/or radiation therapy have been deemed unviable options) for a clinical trial.

The purpose of this study is to test if the combined treatment of the immunotherapy study drug
(atezolizumab) with the standard treatment (platinum-based chemotherapy (carboplatin or cisplatin) plus
anti-body and chemotherapy drugs (bevacizumab and paclitaxel)) could stop or reverse the progression of
cervical cancer. Disease response and the side effects of the two treatments (Study treatment vs. Standard of
Care Treatment) will be studied as part of this clinical trial. The participants will not be able to choose which
combination of treatment they will be receiving.

If you are eligible and choose to participate, the study-related drugs (atezolizumab and bevacizumab) will be
provided free of charge. Additionally, the cost of the study-related blood samples and tumor biopsy will not
be billed to you or your insurance plan. You and/or your health plan/insurance company will be responsible
for the costs of the medical care you get as part of the study, just as you would if you were getting the usual
care for your cancer.

Additional information can be found here: NCT03556839

Compensation

None